Go back

Summary of results 2023

Results of the Call

Mostrar texto Ocultar texto

  • DATA 2023

    The CaixaImpulse Health Innovation Call 2023 has awarded a total of €3.3 millions to 29 health innovation projects. Of the finalist projects, two have been selected in collaboration with the Fundação para a Ciência e a Tecnologia (FCT) of the Ministério da Ciência, Tecnologia e Ensino Superior de Portugal.

    Information regarding the CaixaImpulse Health Innovation Call 2023 and the results are presented below: number of proposals submitted, pre-selected and selected projects by business area and project maturity, as well as the territorial distribution of the selected projects.

    CAIXAIMPULSE 2023 CALL

    Total budget

    € 3,321,911

    Number of proposals submitted

    318

    Number of eligible proposals

    315

    Number of projects pre-selected

    70

    Number of projects selected

    29

    Success rate

    9.1 %

    Table 1: General information of the CaixaImpulse Health Innovation Call 2023.

    Figure 1: Number of proposals submitted by territory

    Figure 1: Number of proposals submitted by territory.

    Figure 2: Number of projects selected by territory

    Figure 2: Number of projects selected by territory.

    PROJECT PHASE

    PROPOSALS SUBMITTED

    PROJECTS PRESELECTED

    PROJECTS SELECTED

    Phase 1

    188

    30

    16 %

    15

    8 %

    Phase 2

    108

    30

    28 %

    12

    11 %

    Phase 3

    22

    10

    45 %

    2

    9 %
     

    318

    70

    22 %

    29

    9 %

    Table 2: Success rate by project phase.

    PROJECT PHASE

    THERAPEUTIC

    MEDICAL TECHNOLOGY AND DIGITAL HEALTH

    TOTALS

    Phase 1

    6

    9

    15

    Phase 2

    6

    6

    12

    Phase 3

    1

    1

    2
     

    13

    16

    29

    Table 3: Number of projects selected by thematic area and project phase.

    PROJECT LEADER

    PROPOSALS SUBMITTED

    PROJECTS PRESELECTED

    PROJECTS SELECTED

    Women

    156

    38

    24 %

    16

    10 %

    Men

    162

    32

    20 %

    13

    8 %
     

    318

    70

    22 %

    29

    9 %

    Table 4: Success rate by gender.

Evaluation process

Mostrar texto Ocultar texto

  • REMOTE EVALUATION PHASE

    • Of the 318 proposals presented, only three were considered ineligible.

    • The proposals were evaluated by a total of 82 experts: at least two per project.

    • The proposals were assigned through a project and evaluator matching process, taking into account the business area, thematic areas and sub-areas, and the phase of the programme to which they were presented.

    • The final score for each project was adjusted based on two standardisation coefficients related to the mean and dispersion of scores for each evaluator.

    • There were four proposals with a discrepancy of more than 2.5 points and with the possibility of passing to the interview phase, which were evaluated by third evaluator. The mean score was calculated taking into account the three standardised scores.

  • INTERVIEW PHASE

    The top 30 proposals from phases 1 and 2 and the top 10 from phase 3, according to the ranking established with the remote evaluation scores, proceeded to this phase.

    The interviews were evaluated by differentiated panels for each of the phases (1, 2 or 3) and the business areas of the projects (Therapeutic, MedTech and Digital Health). These panels were made up of four to eight experts selected for their depth of knowledge and area of expertise, in addition to a member from Caixa Capital Risc.

    The process was as follows:

    • Face-to-face interviews with presentation of the project followed by questions.

    • Discussion and recording in the system of the evaluation results of each project by the panel members. The evaluation is binary in nature (Go / No go).

    • Presentation of the initial ranking of projects based on the percentage of goes that each project receives according to the number of votes cast.

    • Discussion, deliberation and, if necessary, adjustment of the evaluations by members of the panel.

    • Presentation of the final ranking.

     

    Of the selected proposals, it was proposed that two from phase 3 should enter the programme as phase 2, and that two from phase 2 enter as phase 1, based on the recommendation of their respective evaluation panels.

    Finally, 29 proposals were funded, 27 by funds from the ”la Caixa” Foundation, and two by funds from the Portuguese government agency Fundação para a Ciencia e a Tecnología, in the framework of the collaboration established between the two institutions.

  • LIST

Summary of selected projects

Mostrar texto Ocultar texto

See each selected project

CODE

TITLE

PROJECT LEADER

CENTRE

MODALITY

PARTNER INSTITUTIONS

STAGE

BUSINESS AREA

BUDGET (€)

CI23-10022

Smart dendritic contrast agent for accurate stroke diagnosis by computed tomography

Victoria Leiro

i3S – Instituto de Investigação e Inovação em Saúde da Universidade do Porto - Associação

Individual

N/A

STAGE
1

Diagnostics

49,996(*)

CI23-10074

Pre-clinical development of a DNA vaccine to elicit immunity against K. pneumoniae virulence factors

Mireia López

Universitat de Girona

Individual

N/A

STAGE
1

Therapeutics

50,000

CI23-10079

Overcoming resistance to virotherapy for pediatric brain tumors

Marta Alonso

Fundación para la Investigación Médica Aplicada (FIMA/CIMA)

Individual

N/A

STAGE
1

Therapeutics

50,000

CI23-10134

Nano-coatings for prosthetics based on microbial phenazines conjugated with silver nanostars

Pedro Soares

Instituto de Medicina Molecular

Individual

N/A

STAGE
1

Medical Devices

50,000

CI23-10157

Revolutionizing Electronic Skin: Biobatteries Powered
by Collagen-based biomaterials

Ana Pina

Universidade Nova de Lisboa

Consortium

Materials Research
Center (CENIMAT) of the Associated Laboratory i3N, Institute of Nanostructures, Nanomodeling and Nanofabrication (I3N), Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa (FCT-NOVA)

UCIBIO - Applied Molecular Biosciences
Unit, Associate Laboratory
i4HB - Institute for Health and Bioeconomy, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa (FCT-NOVA)

Instituto de Tecnologia - Química e
Biológica, Universidade Nova de Lisboa (ITQB-NOVA)

Instituto Gulbenkian de Ciência

STAGE
1

Medical Devices

49,000

CI23-10184

Luminopsins in Parkinson’s disease stimulation

Luisa Lopes

Instituto de Medicina Molecular

Individual

N/A

STAGE
1

Therapeutics

50,000

CI23-10272

A versatile and stress-resistant biocatalyst nanoplatform for pathogen detection

Mónica Serrano

Universidade Nova de Lisboa

Individual

N/A

STAGE
1

Diagnostics

49,000

CI23-10330

A novel liquid biopsy approach for early breast cancer detection in lactating women

Ana Vivancos

Fundació privada Institut Investigació Oncologica Vall Hebron (VHIO)

Individual

N/A

STAGE
1

Diagnostics

50,000

CI23-10376

Preliminar demonstration and valorization of therapeutic rewiring of (partially) severed spinal cord

Maurizio Prato

Asociación Centro de Investigación Cooperativa en Biomateriales

Individual

N/A

STAGE
1

Medical Devices

50,000

CI23-10380

New subset of neutrophils as a biomarker and a therapeutic target for metastatic breast cancer

Maria de Guadalupe Gonçalves

Universidade Nova de Lisboa

Individual

N/A

STAGE
1

Therapeutics

49,000(*)

CI23-10420

Targeting microtubule polyglutamylation for cancer therapy

Isabelle Vernos

Centre de Regulació Genòmica (CRG)

Individual

N/A

STAGE
1

Therapeutics

50,000

CI23-10434

RACE Plus: AI-driven application to allow pre-hospital diagnosis and management of stroke patients

Natalia Pérez de la Ossa

Fundació Institut d’Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)

Individual

N/A

STAGE
1

Digital Health

50,000

CI23-10562

Developing a new therapeutic approach to overcome resistance to checkpoint inhibitors

Rodrigo Toledo

Fundació privada Institut Investigació Oncologica Vall Hebron (VHIO)

Individual

N/A

STAGE
1

Therapeutics

48,700

CI23-20154

New Biomarker for NAFLD and NASH Development and Progression

David Martinez

Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)

Individual

N/A

STAGE
1

Diagnostics

50,000

CI23-20369

CarboSign7 for pancreatic cancer diagnosis: Biosampling optimization

Oscar Pozo

Fundació Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)

Consortium

Hospital del Mar - Parc de Salut MAR

STAGE
1

Diagnostics

50,000

CI23-20043

Novel gut-restricted first-in-class therapy for Inflammatory Bowel Disease

Isabel Huber

Fundació Institut d'Investigació Sanitària Pere Virgili

Individual

 

STAGE
2

Therapeutics

150,000

CI23-20067

Novel far-red/NIR-activatable PDT agents for combating hypoxic tumors

Vicente Marchán

Universitat de Barcelona

Individual

N/A

STAGE
2

Therapeutics

150,000

CI23-20148

Arteriovenous Fistula for Dialysis: Machine Learning based models for failure and Cardiac events

José Ibeas

Fundació Institut d'Investigació i Innovació Parc Taulí (I3PT)

Individual

N/A

STAGE
2

Digital Health

150,000

CI23-20210

BlaDimiR, non-invasive urine-based diagnostic and therapy response predictor for bladder cancer

Marta Dueñas

Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre

Individual

N/A

STAGE
2

Diagnostics

143,000

CI23-20216

Biohybrid hydrogels as Artificial Tissues against Cancer

Judith Guasch

Consejo Superior de Investigaciones Científicas (CSIC)

Individual

N/A

STAGE
2

Medical Devices

150,000

CI23-20229

Humanized Wnt-11 antibodies for cancer therapy: further validation and asset development

Robert Kypta

Asociación Centro de Investigación Cooperativa en Biociencias-CIC bioGUNE

Individual

N/A

STAGE
2

Therapeutics

150,000

CI23-20433

Microbiome-associated biomarkers for improved anal cancer prevention

Sergio Serrano-Villar

Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal

Consortium

Instituto de Catálisis y Petroleoquímica (ICP), CSIC Marie Curie, 2 – 28049 Madrid, Spain

STAGE
2

Diagnostics

135,261

CI23-20487

Proof of concept for development of an ATMP based on modified pericytes for glioblastoma treatment

Rut Valdor

Universidad de Murcia

Individual

 

STAGE
2

Therapeutics

150,000

CI23-20514

Duacept, a novel bi-specific fusion protein to prevent transplant rejection

Oriol Bestard

Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)

Individual

N/A

STAGE
2

Therapeutics

148,500

CI23-20559

DUFIC, a device for in vivo uterine fluid collection

Pilar Coy

Universidad de Murcia

Individual

N/A

STAGE
2

Medical Devices

149,500

CI23-30155

Treating Liver Disease with Therapeutic RNA

Maria Luz Martinez

Asociación Centro de Investigación Cooperativa en Biociencias-CIC bioGUNE

Individual

N/A

STAGE
2

Therapeutics

150,000

CI23-30260

MICROSCREEN_CRC: Microbial biomarker test for early diagnosis of colorectal cancer (MiCRC)

Olfat Khannous

Fundació Institut de Recerca Biomèdica (IRB Barcelona)

Individual

N/A

STAGE
2

Diagnostics

150,000

CI23-30015

FIBROKIT: First IVD-based non-invasive monitoring of kidney fibrosis

Francesc E. Borras

Fundació Institut d’Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)

Individual

N/A

STAGE
3

Diagnostics

300,000

CI23-30316

LCOR mRNA NanoTherapies - A paradigm shift in immunotherapies against cancer

Toni Celià-Terrassa

Fundació Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)

Individual

N/A

STAGE
3

Therapeutics

500,000

(*) Project cofunded by the Fundação para a Ciência e a Tecnologia (FCT)